Researchers have in recent years sought to establish whether the general public value treatment at the end of life (EOL) more highly than other treatments. Results are mixed, with social preferences most often exhibiting lack of preferences for EOL treatments. This null result may be driven by the often applied study design, where respondents are to choose between treatments targeting patients with varying fixed life expectancies. When remaining life is certain and salient, a rule-of-rescue sentiment may drive preferences across all scenarios. This study presents a different design, where the comparator is a preventive intervention. We study preferences from both an individual and social perspective and find no preference for an EOL premium.
| INTRODUCTION
A pertinent issue in health policy in recent years is whether to place a premium on the value of health gains at the end-of-life (EOL). There are today various treatments available that offer limited extension of life, or improved quality of life, at the EOL. In 2009, NICE established that in cases of EOL treatment, the Appraisal Committee should consider giving greater weight to Quality Adjusted Life Years (QALYs) (NICE, 2009 ). NICE's EOL guidance for its Committees thus effectively advises them to deviate from the Institute's threshold range and to value the lives of EOL patients more than the lives of those suffering from other, potentially curable, chronic or acute conditions (Chalkidou, 2012) .
In the aftermath of this decision, researchers have sought to establish whether the general public do indeed have a preference for an EOL premium (Linley & Hughes, 2013; Olsen, 2013; Pennington, Baker, Brouwer, et al., 2015; Pinto-Prades, Sánchez-Martínez, Corbacho, & Baker, 2014; Rowen, Brazier, Mukuria, et al., 2016; Shah, Tsuchiya, & Wailoo, 2014; Shah, Tsuchiya, & Wailoo, 2015; Skedgel, Wailoo, & Akehurst, 2015) . These studies apply different perspectives (primarily social) as well as different comparators. In all studies, the perspective is ex post. Respondents are asked to choose between providing treatment to others (or themselves) after diagnosis when they face a shorter life expectancy (LE) without treatment. The problem with this approach is that although analysts may define EOL as >2 years of remaining LE, this definition is not necessarily shared by (all) respondents. The mere presentation of LE as certain and salient may be interpreted as a life sentence irrespective of whether LE is 1 or 10 years. Rowen et al. (2016) present LEs of between 3 months and 5 years and find a preference for EOL treatment (defined as LE ≤ 2 years). Shah et al. (2015) operate with similar LEs (3 to 60 months, also with a cutoff at 2 years) but find no support for an EOL premium. In Shah et al. (2014) , the trade-off involves 1 versus 10 years of remaining LE, and the authors find weak evidence of preference for EOL treatment. In contrast, Olsen (2013) asks respondents to trade-off treating patients with 1, 3, or 10 years of remaining LE versus treating the young or obtaining larger health gains and finds no preference for EOL treatment. The majority of the studies that look at how length of LE without treatment affects preferences demonstrate no support for EOL. Skedgel et al. (2015) even find an aversion towards EOL treatment (when operating with LEs of 1 month, 5 years, and 10 years). Pinto-Prades et al. (2014) apply a different methodology. Respondents are asked to trade off health gains targeting intermediate health states with health gains at the EOL and find a preference for EOL treatments. In this case, the difference in post intervention outcomes (extension of life versus improvement in quality of life) is potentially an important driver of preferences for EOL. Based on these results, one cannot, however, infer that EOL treatment should be prioritised over other life extending health care interventions. Pennington et al. (2015) and Pinto-Prades et al. (2014) found evidence of preference for EOL treatment when applying an ex post individual perspective and measuring strength of preference by way of willingness to pay. However, in both cases, respondents are asked to imagine that their remaining LE is short, which is likely to generate a marked decrease in marginal utility of income. Such a decrease in marginal utility of income will ceteris paribus increase willingness to pay and thus confound the association between willingness to pay and EOL treatment.
In the present study, we seek to extend the aforementioned literature by applying an ex ante insurance approach (as opposed to the usual ex post perspective), which excludes the presence of health state-dependent marginal utility of income. Our design also differs in choice of comparator. We compare EOL treatment (defined as smaller extensions to life when death will occur within a few months without treatment) with a preventive treatment that offers life extension and the same expected health gain. An additional contribution is that we test whether the preference for EOL treatment depends on the age of potential recipients. This is in contrast to most other studies, which have either ignored age altogether or asked respondents to trade-off preferences for EOL with preferences for age. Further, respondents are randomised to scenarios in which they are asked to act as either themselves or social decision makers, in order to verify how social and individual preferences differ ceteris paribus. This is important because prior studies have applied both perspectives without a direct comparison.
| METHODS
A random sample of Danish respondents was asked to prioritise between having access to four different treatments. Respondents could not state indifference but were to indicate the one treatment that they preferred. Respondents were to make this choice from either an individual or social perspective. The four treatments offered the same expected health gain (1 year in good health), but the context differed, see Table 1 . EOL treatment was in the present study exemplified by a certain 1-year extension of life after diagnosis of a disease with fatal outcome within a short time horizon without treatment (C, D) as opposed to treatments that are provided to avoid a fatal diagnosis and thus offer longer life extensions, but with a high degree of uncertainty (A, B). We test preferences for two age groups: 50-60 years (A, C) and 70-80 years (B, D).
Respondents were randomised to one of the following two question frames (the original presentation was in Danish).
| Individual perspective
"Imagine that you have a private insurance policy. The insurance company offers you a free extension of your policy such that it covers the cost of an extra health care service, which is not covered by the national insurance scheme. You can choose between four health care services of which only one can be included in your insurance coverage. The treatments are expensive and difficult to access if one is not insured. There is an equal chance that you may need treatment for illness A, B, C, or D, which all have similar symptoms. The four treatments offer the same expected health gain (1 year). Which treatment would you choose to include in your insurance policy?"
| Social perspective
"Imagine that one wishes to introduce one of four new treatment under the national health care service in a country where you do not live. There are available resources for this treatment under the present health care budget, due to efficiency improvements. There is a choice of four health care services of which only one can be included under the national health care service. The treatments are expensive and difficult to access if one is not insured. There is an equal chance that citizens may need treatment for illness A, B, C, or D, which all have similar symptoms. The four treatments offer the same expected health gain (1 year). Which treatment do you think the politicians should choose to include under the national health care service?"
Respondents (aged 25-79 years) were recruited from a Danish internet panel administered by Nielsen. The survey went online November 19, 2013, and closed on December 2, 2013. We aimed at recruiting 2,000 respondents. A general invitation was sent out (no information on the content of the survey was provided), and 3,303 respondents chose to access the survey. Of the 3,303 who accessed the survey, 2,000 finalised before the link was closed. Due to mode of operation (inviting a large number of panel members to participate by e-mail and closing when sufficient number of responses were obtained), a standard response rate cannot be estimated. The survey was relatively short and involved warming up questions relating to age, gender, own health, and supplementary insurance status. Half of the 2,000 respondents were randomised to answering one of the insurance questions presented above.
In choice scenarios A and B, respondents are presented with two dimensions of the expected health outcome: probability and life extension. To ensure that individuals do not only pay attention to one type of information, we modelled our presentation of this information on a previous stated preference study (same orders of magnitude and same presentation format), which demonstrated high sensitivity to both dimensions (Gyrd-Hansen & Kristiansen, 2008) .
The choice scenario is designed such that there is a bias towards choosing EOL treatment if respondents have positive time preferences, are risk averse, or have preferences for an equitable distribution of health (social perspective), because EOL offers an expected health gain that is more certain and obtained sooner. Hence, if EOL is not the preferred option, this is a strong result. If EOL is preferred, this may be because EOL treatment is often characterised by the aforementioned traits.
| RESULTS
Five hundred respondents were randomised to each of the two question formats, and all chose to provide an answer (it was possible to leave the question unanswered). The respondents were representative of the Danish population with respect to age and gender, but those with higher levels of education were overrepresented. There was no difference in age, gender, income, or education level across the two split samples.
The results of the stated preference choice scenarios for both perspectives are presented in Table 2 . Results are presented for all respondents, as well as for those under 50 years of age, in order to ascertain whether older age, and thus proximity to the hypothetical scenarios affect preference structures. Overall, preference structures are the same across age groups.
Our results do not indicate that EOL treatments are prioritised over treatments that are preventive. More respondents prefer A to C and B to D, and this pattern is consistent across perspectives and age groups. Also, A + B > C + D (p < .001) for both the individual and social perspectives). Moreover, C > D, indicating that preference for EOL treatment is strongest for younger age groups.
gains and/or a reduction in certainty of the outcome for the individual participant and despite the more equitable distribution of health gains generated by the EOL treatment, which may generate stronger social preferences.
Preferences for EOL are stronger for the 50-60 year olds than for the 70-80 year olds. The finding that young age groups are prioritised is in line with a number of studies (see e.g., Dolan & Tsuchiya, 2005; Mak, Woo, Bowling, Wong, & Chau, 2011) .
We omitted the concept of willingness to pay and chose a framework of a constrained budget where opportunity costs are represented in terms of alternative health care services. We see this as an advantage of the study design as this this is more in line with real priority setting scenarios. Also, our design avoids the problem of marginal utility of income confounding results in the individual perspective.
Not all respondents may have understood exactly how treatment alternatives A and B are preventive. A more detailed description would have required explanation of whether prevention was primary or secondary prevention, and thus involved greater complexity. However, for our conclusions to hold, it is not necessary that all respondents have paid great attention to the prevention label of A and B. What is more important is that the respondents have focused on the distributional characteristics of the health outcomes. Treatment at the late stage of disease (such as chemotherapy given to patients with late stage cancer) will generally provide small life extensions to a majority of patients. In contrast, many primary and secondary preventive efforts will offer the possibility of a cure and thus large gains to the few (as in the case of cancer screening programmes, statin treatment and treatment for hypertension). Our findings suggest that respondents prefer the latter when they are behind a veil of ignorance and potentially face the need for both types of treatments.
In conclusion, our results complement the existing literature by measuring the preferences for EOL treatment vis-à-vis preventive interventions. We present results from both an individual and a social perspective. We find no evidence of a general preference for EOL treatment over preventive interventions. We observe that it is generally preferred to offer EOL treatment to individuals who are younger.
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